{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:49:23Z","timestamp":1790786963893,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2019-12368903"],"award-info":[{"award-number":["GR-2019-12368903"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100506","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T20:27:56Z","timestamp":1654892876000},"page":"100506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Boccaccino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Intini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Antista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rihawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Libertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100506_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib2","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100506_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib6","series-title":"BRAFTOVI\u00ae (encorafenib) Summary of Product Characteristics","year":"2018"},{"key":"10.1016\/j.esmoop.2022.100506_bib7","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/j.annonc.2021.06.010","article-title":"LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR\u00a0+\/- MEK inhibitors","volume":"32","author":"\u00c9lez","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/1878-0261.12099","article-title":"Analysis of mutant allele fractions in driver genes in colorectal cancer \u2013 biological and clinical insights","volume":"11","author":"Dienstmann","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oncolo\/oyab030","article-title":"Efficacy and safety of\u00a0cetuximab dosing (biweekly vs weekly) in patients with KRAS wild-type metastatic colorectal cancer: a meta-analysis","volume":"27","author":"Parikh","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100506_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3619","article-title":"BREAKWATER: randomized phase 3 study of encorafenib (enco)\u00a0+ cetuximab (cetux) \u00b1 chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib12","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/1878-0261.12547","article-title":"Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer","volume":"13","author":"Elez","year":"2019","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-20-2710","article-title":"Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 Trial","volume":"27","author":"Loree","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100506_bib14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/annonc\/mdv176","article-title":"Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial","volume":"26","author":"Normanno","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib15","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.3390\/ijms19123733","article-title":"Heterogeneity in colorectal cancer: a challenge for personalized medicine?","volume":"19","author":"Molinari","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100506_bib16","doi-asserted-by":"crossref","first-page":"100211","DOI":"10.1016\/j.esmoop.2021.100211","article-title":"Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas","volume":"6","author":"Angerilli","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100506_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.06.008","article-title":"A\u00a0validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the \u2018BRAF BeCool\u2019 study","volume":"118","author":"Loupakis","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100506_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00397","article-title":"Circulating tumor DNA analysis in colorectal cancer: from dream to reality","volume":"3","author":"Antoniotti","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib20","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1016\/j.annonc.2021.05.014","article-title":"O-10 ANCHOR CRC: results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E\u2013mutant metastatic colorectal cancer","volume":"32","author":"Van Cutsem","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100506_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100506_bib22","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:18Z","timestamp":1761856158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2059702922001260"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100506","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100506"}}